Prostate Cancer Nuclear Medicine Diagnostics Market Insights, Global Outlook and Forecast 2022-2028
Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Nuclear medicine, a type of imaging that uses radioactive materials, is a useful tool to detect and also treat prostate cancer. It is a form of diagnostic imaging that helps radiologists determine the stage of cancer.
The latest research study released by Market IntelliX evaluates market size and forecasts of Prostate Cancer Nuclear Medicine Diagnostics in Global, including the following market information:
Global Prostate Cancer Nuclear Medicine Diagnostics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Prostate Cancer Nuclear Medicine Diagnostics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
SPECT Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Prostate Cancer Nuclear Medicine Diagnostics include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, Jubilant Pharma, NCM-USA, Progenics Pharma, Telix Pharma and ImaginAb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MI has surveyed the Prostate Cancer Nuclear Medicine Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Market Segmentations:
Global Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, by Type, 2021 (%)
SPECT
PET
Global Prostate Cancer Nuclear Medicine Diagnostics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Prostate Cancer Nuclear Medicine Diagnostics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Prostate Cancer Nuclear Medicine Diagnostics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Prostate Cancer Nuclear Medicine Diagnostics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Prostate Cancer Nuclear Medicine Diagnostics revenues share in global market, 2021 (%)
The report presents profiles of competitors in the market, Some of the prominent key players covered:
Blue Earth Diagnostics
PETNET Solutions
Cardinal Health
Lantheus Medical Imaging
Jubilant Pharma
NCM-USA
Progenics Pharma
Telix Pharma
ImaginAb
Theragnostics
Novartis
Alliance Medical
Key Takeaways from this Report
Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.
Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.
Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
Analyze the sales and distribution channels across key geographies to improve top-line revenues.
Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.
Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.
Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.
1 Introduction to Research & Analysis Reports
1.1 Prostate Cancer Nuclear Medicine Diagnostics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Prostate Cancer Nuclear Medicine Diagnostics Overall Market Size
2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size: 2021 VS 2028
2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market
3.2 Top Global Prostate Cancer Nuclear Medicine Diagnostics Companies Ranked by Revenue
3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Companies
3.4 Top 3 and Top 5 Prostate Cancer Nuclear Medicine Diagnostics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Prostate Cancer Nuclear Medicine Diagnostics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Players in Global Market
3.6.1 List of Global Tier 1 Prostate Cancer Nuclear Medicine Diagnostics Companies
3.6.2 List of Global Tier 2 and Tier 3 Prostate Cancer Nuclear Medicine Diagnostics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Markets, 2021 & 2028
4.1.2 SPECT
4.1.3 PET
4.2 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
4.2.1 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2022
4.2.2 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2023-2028
4.2.3 By Type - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2021 & 2028
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
5.2.1 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2022
5.2.2 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2023-2028
5.2.3 By Application - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2021 & 2028
6.2 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue & Forecasts
6.2.1 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2022
6.2.2 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2023-2028
6.2.3 By Region - Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.3.2 US Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.4.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.4 U.K. Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.5 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.6 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.7 Nordic Countries Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.4.8 Benelux Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.5.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.5 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.5.6 India Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.6.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.6.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue, 2017-2028
6.7.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7.3 Israel Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7.4 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
6.7.5 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size, 2017-2028
7 Players Profiles
7.1 Blue Earth Diagnostics
7.1.1 Blue Earth Diagnostics Corporate Summary
7.1.2 Blue Earth Diagnostics Business Overview
7.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.1.5 Blue Earth Diagnostics Key News
7.2 PETNET Solutions
7.2.1 PETNET Solutions Corporate Summary
7.2.2 PETNET Solutions Business Overview
7.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.2.5 PETNET Solutions Key News
7.3 Cardinal Health
7.3.1 Cardinal Health Corporate Summary
7.3.2 Cardinal Health Business Overview
7.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.3.5 Cardinal Health Key News
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Corporate Summary
7.4.2 Lantheus Medical Imaging Business Overview
7.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.4.5 Lantheus Medical Imaging Key News
7.5 Jubilant Pharma
7.5.1 Jubilant Pharma Corporate Summary
7.5.2 Jubilant Pharma Business Overview
7.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.5.5 Jubilant Pharma Key News
7.6 NCM-USA
7.6.1 NCM-USA Corporate Summary
7.6.2 NCM-USA Business Overview
7.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.6.5 NCM-USA Key News
7.7 Progenics Pharma
7.7.1 Progenics Pharma Corporate Summary
7.7.2 Progenics Pharma Business Overview
7.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.7.5 Progenics Pharma Key News
7.8 Telix Pharma
7.8.1 Telix Pharma Corporate Summary
7.8.2 Telix Pharma Business Overview
7.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.8.5 Telix Pharma Key News
7.9 ImaginAb
7.9.1 ImaginAb Corporate Summary
7.9.2 ImaginAb Business Overview
7.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.9.5 ImaginAb Key News
7.10 Theragnostics
7.10.1 Theragnostics Corporate Summary
7.10.2 Theragnostics Business Overview
7.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.10.5 Theragnostics Key News
7.11 Novartis
7.11.1 Novartis Corporate Summary
7.11.2 Novartis Business Overview
7.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.11.5 Novartis Key News
7.12 Alliance Medical
7.12.1 Alliance Medical Corporate Summary
7.12.2 Alliance Medical Business Overview
7.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Major Product Offerings
7.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue in Global Market (2017-2022)
7.12.5 Alliance Medical Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Research Methodology:
Prostate Cancer Nuclear Medicine Diagnostics Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|